This guide is educational, not a recommendation to use AOD-9604. It contains no dosing or treatment instructions. Sources checked November 8, 2026. No clinician review is claimed.
The clearest answer is less exciting than the marketing: AOD-9604 did not produce a statistically significant weight-loss advantage over placebo in its large oral OPTIONS trial. That result does not prove that every possible formulation would fail. It also does not establish that injections work. Claims about stubborn belly fat, combinations and before-and-after results need evidence the oral trial cannot provide. FDA's 2024 evidence assessment
What is AOD-9604?
AOD-9604 is a synthetic peptide based on a small part of human growth hormone, with an added amino acid. It is not full-length growth hormone. Its relationship to that hormone explains the research interest, not a proven weight-loss benefit. A plausible mechanism or an animal experiment is a starting point for a human trial, not a substitute for one. FDA assessment, background and effectiveness review
Two questions are often blurred together: did people lose weight while taking it, and did it cause more weight loss than a comparable group without it? Controlled trials are designed to address the second question.
What happened in the main human weight-loss trial?
OPTIONS was a randomized, double-blind, placebo-controlled study in adults with obesity. FDA reports that 536 people enrolled and 502 were randomized. Participants received oral tablets or placebo over 24 weeks alongside a dietitian-supervised diet and exercise program. The prespecified primary weight-loss comparison was at 12 weeks, not simply the final change on the scale. FDA assessment, PDF pages 25–26
The original ANZCTR registration, ACTRN12605000067673, also records the oral route, the 24-week treatment period and the 12-week primary weight outcome. It also lists secondary measures including later weight change, waist circumference and body composition. Registration records what investigators planned to study; it is not itself proof of benefit.
The trial did not meet its primary weight-loss endpoint. FDA's review also records the developer's statement that the weight-loss comparisons at both 12 and 24 weeks were too small to reach statistical significance. The company ended development for obesity after the result. FDA noted that detailed methods and efficacy results did not appear to have been published in the medical literature. FDA assessment, PDF pages 25–27
The practical distinction matters. If participants change food intake and activity and then lose weight, that does not identify which part of the program caused the change. The placebo comparison asks whether adding AOD-9604 improved the result beyond the support both groups received. In OPTIONS, that additional benefit was not demonstrated.
Why do some summaries describe positive results?
An earlier 12-week oral study in 300 adults is part of the record too. A conference abstract reported greater weight loss with AOD-9604 than placebo and described the largest effect as significant in women. It would be inaccurate to say that every report showed no signal at all. FDA review of the 2005 abstract
But FDA found the abstract too sparse to assess confidently: it lacked sufficient methods and numerical detail, and the agency did not locate a full publication of the study's methods and results. FDA also questioned the clinical meaning of the small differences. A positive subgroup or preliminary summary should not replace the overall result of the later, larger trial. FDA assessment, PDF pages 24–25
This is why a useful evidence summary names the study, route, comparison group and outcome rather than offering one impressive number without its context.
Does the oral result tell us whether injections work?
Not directly. Route matters. A swallowed tablet, an intravenous research product and a product injected under the skin are not interchangeable evidence categories.
In its 2024 assessment, FDA said it had not found human information for the proposed subcutaneous or transdermal routes. That is a dated assessment, not a claim that an exhaustive search of every possible study has been completed today. The sources reviewed for this guide do not establish a controlled human weight-loss benefit for subcutaneous AOD-9604. FDA assessment, PDF pages 27 and 37
The fair conclusion goes both ways: the oral trial cannot settle every question about another route, but changing the route does not turn an unproven benefit into a proven one. Evidence would need to address the actual formulation and route, meaningful outcomes, a comparison group and safety. “The tablets failed, so injections must work” is not a finding from a clinical trial.
What about stubborn belly fat or combining it with other drugs?
“Belly fat” can mean a visible change around the waist, fat beneath the skin or fat around internal organs. Those are not interchangeable outcomes. A weight change or a waist measurement alone does not establish selective loss from a particular fat compartment.
OPTIONS included waist and body-composition measures among its planned secondary outcomes. That does not establish targeted fat reduction. Neither the registration nor FDA's assessment provides a basis for calling AOD-9604 a proven treatment for stubborn belly fat. Trial registration and FDA evidence assessment
Combination stories create another problem. If someone starts AOD-9604 while also changing another medicine, food intake or training, the result cannot isolate what AOD-9604 added. Before-and-after photographs cannot supply the missing comparison. A persuasive combination claim would need evidence comparing otherwise similar groups with and without AOD-9604, rather than assuming the added ingredient deserves the credit.
What does the safety evidence actually cover?
A 2013 paper summarized six clinical studies using oral or intravenous AOD-9604 and reported favorable tolerability. Two authors were affiliated with the developer. That paper is relevant, but it is not independent confirmation that every formulation or route is safe, and it is not a weight-loss efficacy trial report. Stier, Vos and Kenley, 2013
FDA's current safety-risk page flags possible immune reactions, peptide-related impurities and difficulties characterizing AOD-9604 products. It says the available safety information is insufficient to determine whether harm would occur. FDA also notes serious adverse events that may be associated with AOD-9604 while explicitly saying causality is unclear. An event reported during exposure is not automatically caused by the substance; uncertain causality is also not reassurance that a product is harmless. FDA safety-risk page, checked November 8, 2026
Did the 2026 compounding changes make AOD-9604 approved?
No. A compounding policy is not FDA drug approval, and it does not establish a weight-loss benefit.
As checked on November 8, FDA's safety page places AOD-9604 under substances whose nominations were withdrawn. Calling that a current Category 2 listing is inaccurate; treating withdrawal as a safety clearance is also inaccurate. FDA current listing
HHS's October 30, 2026 notice concerns a limited interim enforcement policy. Its linked Appendix A lists six peptides, and AOD-9604 is not one of them. The notice calls the policy a draft and says it is nonbinding; it also explicitly states that compounded drugs are not FDA-approved. This policy therefore should not be presented as approval or a new access pathway for AOD-9604. Federal Register notice and HHS policy, Appendix A
The takeaway
AOD-9604 has human research, but that is different from demonstrated benefit. Its large oral obesity trial did not show a significant weight-loss advantage, and the evidence reviewed here does not validate injected or targeted belly-fat claims. Safety summaries and compounding discussions do not fill that gap.
If you already keep peptide records, organized dates and notes can make a conversation with a qualified healthcare professional clearer. A tracker cannot establish causality, diagnose a problem or make an experimental substance safe. What to look for in a peptide tracker